UBS Group
REVB icon

UBS Group’s Revelation Biosciences REVB Stock Holding History

UBS Group’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,115
Closed -$4.94K – 10938
2026
Q1 		$4.94K Buy
4,115
+3,934
+2,173% +$7.61K ﹤0.01% 8860
2025
Q4 		$579 Buy
181
+180
+18,000% +$788 ﹤0.01% 9886
2025
Q3 		$3 Sell
1
-62
-98% -$602 ﹤0.01% 10253
2025
Q2 		$563 Buy
63
+34
+117% +$890 ﹤0.01% 9792
2025
Q1 		$918 Buy
+29
New +$1.62K ﹤0.01% 9619
2024
Q4 		– Sell
-213
Closed -$34.9K – 10316
2024
Q3 		$34.9K Buy
213
+71
+50% +$17.1K ﹤0.01% 7048
2024
Q2 		$52.2K Buy
142
+120
+545% +$49.5K ﹤0.01% 6656
2024
Q1 		$11.5K Buy
+22
New +$26.5K ﹤0.01% 7181
2023
Q4 		– Hold
0
– – – 8960
2023
Q3 		– Hold
0
– – – 8976
2023
Q2 		– Hold
0
– -$1.77K – 9514
2023
Q1 		– Hold
0
– – – 8652
2022
Q3 		– Hold
0
– -$6K – 10823
2022
Q2 		– Hold
0
– – – 8713
2022
Q1 		– Hold
0
– – – 9311
2021
Q4 		– Hold
0
– -$12K – 10625
2021
Q3 		– Hold
0
– – – 7783
2021
Q2 		– Hold
0
– – – 7585
2021
Q1 		– Hold
0
– – – 6664

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

UBS Group's REVB Position: Q2 2026 in Review

UBS Group sold out of Revelation Biosciences (REVB) in Q2 2026, closing a stake of 4,115 shares — an estimated $4.94K sold.

UBS Group first reported a position in REVB in Q1 2024 and held it in 8 quarters. The position peaked at $52.2K in Q2 2024. 12 funds tracked by Wall St. Rank hold REVB as of Q2 2026.

  • UBS Group reported no remaining Revelation Biosciences position as of Q2 2026 after selling out during the quarter.
  • UBS Group sold 4,115 Revelation Biosciences shares in Q2 2026, an estimated $4.94K.
  • UBS Group first reported a position in Revelation Biosciences in Q1 2024 and held it in 8 quarters.
  • UBS Group's Revelation Biosciences position peaked at $52.2K in Q2 2024.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.